Registration Dossier
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 202-785-7 | CAS number: 99-76-3
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Basic toxicokinetics
Administrative data
- Endpoint:
- basic toxicokinetics in vitro / ex vivo
- Type of information:
- experimental study
- Adequacy of study:
- weight of evidence
- Study period:
- received: 2. July 2007
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Non-guideline study following a scientifically sound study design (mechanistic study) with sufficient study reporting.
Data source
Reference
- Reference Type:
- publication
- Title:
- Unnamed
- Year:
- 2 007
- Report date:
- 2007
Materials and methods
- Objective of study:
- metabolism
Test guideline
- Qualifier:
- no guideline available
- Guideline:
- other: no "in vitro" guideline available
- Deviations:
- not applicable
- Principles of method if other than guideline:
- Comparison of the hydrolysis of Methylparaben by human and minipig skin and liver microsomes and cytosol.
- GLP compliance:
- not specified
Test material
- Reference substance name:
- Methyl 4-hydroxybenzoate
- EC Number:
- 202-785-7
- EC Name:
- Methyl 4-hydroxybenzoate
- Cas Number:
- 99-76-3
- Molecular formula:
- C8H8O3
- IUPAC Name:
- methyl 4-hydroxybenzoate
- Reference substance name:
- Methylparaben
- IUPAC Name:
- Methylparaben
- Details on test material:
- Supplier: Sigma Chemicals Co., Poole, Dorset, UK
Constituent 1
Constituent 2
- Radiolabelling:
- no
Test animals
- Species:
- miniature swine
- Strain:
- not specified
- Sex:
- male
- Details on test animals or test system and environmental conditions:
- Human breast skin (n = 3) was obtained following breast reduction surgery of healthy female individuals (age 28, 37 and 37). Ethical approval was obtained from the Durham University Hospital, U.K. Human liver (n = 22) was obtained from the liver bank of Toxicology Uint, Newcastle University, U.K.
Liver and dorsal skin from 3 male minipigs (weight 9 +/- 1.1 kg) were obtained from Pfizer, US.
All tissues were stored at -70°C until analysis.
Administration / exposure
- Route of administration:
- other: in vitro study: Methylparaben was added to microsomal fraction
- Vehicle:
- physiological saline
- Details on exposure:
- Subcellular protein (skin, 75 µg or liver, 5 µg) was incubated with Methylparaben (100 µM) for 1 hour at 37°C in phosphate buffer (0.1 M, pH 8.0) in a total volume of 250 µL. The reaction was stopped by addition of 750 µL Methanol containing internal standard 3,4-Dihydroxybenzoic acid (100 µM).
- Duration and frequency of treatment / exposure:
- 1 hour at 37°C
Doses / concentrations
- Remarks:
- Doses / Concentrations:
100 µM
- No. of animals per sex per dose / concentration:
- humans: 3 females
minipigs: 3 males - Control animals:
- other: blank sample without protein
- Positive control reference chemical:
- n.a.
- Details on study design:
- - Subcellular fraction preparation:
Human and minipig skin were cut with a dermatome (350 µm) to obtain the epidermis and minimal thickness of upper dermis. This was done to obtain the highest concentration of esterases, as they are predominantly located at the basal layer of epidermis. Tissue was weighed, minced, and pulverised in liquid nitrogen with a mortar and pestle. Pulverised tissue was added to ice-cold KCl/phosphate buffer (150 mM KCl, 0.1 M K2HPO4, ph 7.4) 1 mL per 100 mg tissue. Tissue was homogenised with an Ultra-turrax homogeniser with 3 x 10 sec bursts. The homogenate was centrifuged for 10 min at 750xg followed by ultra-centrifugation of the supernatant for 10 min at 10,000xg to remove mitochondria, nuclei and cell debris. Further centrifugation of the supernatant for 70 min at 100,000xg separated the microsomes from the cytosol. Cytosol was retained and stored at -70°C. The microsomal pellet was resuspended with buffer and centrifuged at 100,000xg for 70 min and the pellet resuspended in glycrol buffer (10% glycerol, 0.05 M Tris, 0.1 mM KCl, 250 mM sucrose, pH 7.4) and stored at -70°C for analysis. Microsomes and cytosol were prepared from liver by the above method without the liquid nitrogen pulverisation. The samples were frozen at -70°C.
- Determination of Methylparaben by HPLC:
Methylparaben and the internal standard Dihydroxybenzoic acid were analysed by HPLC using a Varian ProStar system with UV detection. A Gemini microbore 5 µmx250 mmx2 mm column was used (Phenomenex). Solvant A was water with 1% formic acid and solvent B was Methanol with 1% formic acid. The gradient was run from 35% B to 95% B over 6 min and held at 95% B for 4 min at a flow rate of 0.4 mL/min. The column was allowed to re-equilibrate for 5 min between runs. Column temperature was maintained at 40°C. Sample injection volume was 10 µL and peaks were detected at 264 nm. Retention times were: 4-Hydroxybenzoic acid 3.5 min, Dihydroxybenzoic acid 4.8 min, Methylparaben 6.2 min.
- Determination of Methylparaben hydrolysis by skin and liver microsomes and cytosol:
After the reaction was stopped (please refer to "Details on Exposure") the samples were vortexed for 10 sec and then centrifuged at 3000xg for 10 min. The supernatant was analysed by HPLC. Protein concentration in the reaction was at a level to give sufficient metabolite for analysis but resulting in less than 10% conversion of parent, to ensure linearitiy of reaction over the 1-hour incubation period. Blank incubation were conducted in the absence of protein to determine spontaneous hydrolysis. In a parallel set of incubations, Paraoxon (1mM), Bis-nitrophenyl phosphate (1 µM) and Loperamide (20 µM) were added to the incubation for 20 min before addition of Methylparaben. - Details on dosing and sampling:
- Please refer to "Details on study design"
- Statistics:
- Enzyme activities were expressed as µmol 4-Hydroxybenzoic acid formed/min/mg protein (n =3, mean +/- S.E.M). Activities were compared by ANOVA followed by the post hoc Dunnett´s test. Activities in the presence of inhibitors were expressed as a percentage of the control.
Results and discussion
- Preliminary studies:
- No data
Toxicokinetic / pharmacokinetic studies
- Details on absorption:
- n.a., metabolism study
- Details on distribution in tissues:
- n.a., metabolism study
- Details on excretion:
- n.a., metabolism study
Metabolite characterisation studies
- Metabolites identified:
- yes
- Details on metabolites:
- Please refer to "Remarks on results including tables and figures"
Any other information on results incl. tables
Microsomal and cytosolic fractions displayed similar hydrolysis rates for both human and minipig skin. The rates were similar for both microsomal and cytosolic fractions.
a.) hydrolysis of Methylparaben by human/minipig skin
microsomal (human): 0.4 µmol/min/mg protein
microsomal (minipig): appr. 0.4 µmol/min/mg protein
cytosolic (human): 0.55 µmol/min/mg protein
cytosolic (minipig): 0.56 µmol/min/mg protein
Methylparaben hydrolysis rates using liver fractions were significantly higher than for skin microsomes or cytosol. The hydrolysis of the test item by human liver microsomes was also significantly higher (nearly 5 -fold) than minipig liver microsomes (p<0.001).
b.) hydrolysis of Methylparaben by human/minipig liver:
microsomal (human): 260 µmol/min/mg protein
microsomal (minipig): 40 µmol/min/mg protein
cytosolic (human): 24 µmol/min/mg protein
cytosolic (minipig): 14 µmol/min/mg protein
Pre-incubation of human or minipig skin subcellular fractions with Paraoxon (1µM) or Bis-nitrophenyl phosphate (1µM) completely inhibited the hydrolysis of Methylparaben. Loperamide (20 µM) had no effect on the hydrolysis by human or minipig microsomal or cytosolic skin fractions.
Applicant's summary and conclusion
- Conclusions:
- Interpretation of results (migrated information): other: Methylparaben hydrolysis rates using liver fractions were significantly higher than for skin microsomes or cytosol.
Microsomal and cytosolic fractions displayed similar hydrolysis rates for both human and minipig skin. The rates were similar for both microsomal and cytosolic fractions.
Methylparaben hydrolysis rates using liver fractions were significantly higher than for skin microsomes or cytosol. The hydrolysis of the test item by human liver microsomes was also significantly higher (nearly 5 -fold) than minipig liver microsomes (p<0.001). - Executive summary:
Methylparaben was hydrolysed by both liver and skin microsomal/cytosolic fraction of humans and minipigs. The hydrolysis by human esterases was higher than that observed for minipigs.
In this study, significantly different rates of hydrolysis and effect of the inhibitor Loperamide suggest that Methylparaben may be preferentially hydrolysed in the skin by one carboxylase isoform, hCE1 since Loperamide has been shown to specifically inhibit hCE2.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.

Route: .live1